Connect with us


Addisons Disease and CBD Treatments



There is a dysfunction that is quite rare and of completely unknown origin that represents a disorder of the adrenal cortex. It is sometimes called Primary Adrenal Insufficiency, but is more commonly known as Addison’s Disease.

The condition is characterized by unstable mood, potential adrenal crisis, weight loss, general lack of appetite, and fatigue. When adrenal crisis is present, one will often observe a sharp drop in blood pressure accompanied by a state of dizziness, fainting, and pain in the lower half of the body. Such an attack can even be fatal, and emergency services should be contacted immediately.

Understanding Addison’s Disease

As noted above, this is an issue characterized by a dysfunction of the adrenal cortex, which is essentially made of two glandular organs that can be found on the roof of the kidneys in the human body.

All of this really comes down to what is known as the hypothalamic-pituitary-adrenal axis, also known as the HPA. This is essentially the nexus point that connects the human endocrine and central nervous systems.

The endocrine system is basically the regulatory system overseeing hormones and signaling molecules that are in charge of a number of different chemical processes of a regulatory nature in the systematic functionality of mammalian physiology.

The adrenal system is basically a part of this, and is in charge of things like our fight or flight reflex and our ability to ramp up bodily processes to respond to danger, stress, or high emotion situations. The pituitary gland is basically in charge of most of this. It does its work through the production of mineralocorticoids and glucocorticoids.

Addison’s disease is basically about a situation when the adrenal cortex undergoes an autoimmune assault or atrophies for unknown reasons. The net result is that it no longer produces the hormones necessary to allow the regulatory processes of the human body to function properly.

You can imagine why this could be such a problem. We need our regulatory systems in our body to maintain proper functioning of our physiological systems because so much going on in the body depends upon proper levels of different chemicals in any system at any given time. Various bodily systems work together, hand in hand, on so many different levels that a systematic breakdown of any one of these regulatory functions can be nearly or entirely impossible for medical science to treat.

While much of what we do to maintain our health on a daily basis is really about maintaining these systems and preventing problems, sometimes, for certain individuals, such regulatory breakdowns and physiological problems are inevitable, and so some sort of therapy or treatment is necessary.

CBD and Addison’s Disease

While this is a very uncommon disease, it may be tailor-made as an excellent candidate for treatment or therapy involving cannabidiol, or CBD.

As we have discussed at length, the endocannabinoid system is intimately tied into most of the body’s various regulatory functions. Because many cases of Addison’s disease derive in some way from an inflammatory autoimmune problem, CBD may play an important role in solving this dilemma. You see, much of the body’s inflammatory autoimmune reactions are governed by failures of the proper functioning of the endocannabinoid system.

As we have found through much anecdotal evidence and some research, introduction of cannabidiol can restore the proper functional balance of the endocannabinoid system in the human body, thereby allowing it to properly regulate an overly excited inflammatory autoimmune response.

As such, CBD may be excellent in preventing the onset of the more developed phase of Addison’s disease. However, this means it would need to be administered before higher-level symptoms have occurred, which could mean daily application by individuals who don’t even realize that there is risk of contracting this difficult disease.

In addition, CBD may also be able to relieve many of the symptoms, including mood instability, fatigue, vascular issues, and lack of appetite, that are often associated with Addison’s disease.

One enzyme pathway that may be intimately involved in the pathogenesis of this condition is cytochrome P450, or CYP450. One of the specific enzymes on this pathway, 21-hydroxylase, has been found to be involved in over 80% of all Addison’s cases.

As a strong indication of promise, CBD has been shown to block the autoimmune response to this vital enzyme. We don’t know exactly why this seems to work so well, but it’s good to know that it does.


Continue Reading


CannTrust Holdings Inc (NYSE:CTST) Penetrates Into The United States After Investing $20 Million



CannTrust Holdings Inc (NYSE:CTST), a Canadian company that produces and sells medical and recreational marijuana has announced the expansion of its business into the United States.

The Canadian firm revealed that it signed a Letter of Intent through which it will start working with Elk Grove Farming Company, LLC to access more than 3,000 hemp production acres in California. The two companies struck a joint partnership that will allow CannTrust to secure a footing in the California market which is one of the biggest cannabis markets in the U.S.

“This agreement represents another bold move for CannTrust. Our U.S. operation is expected to deliver a significant increase in low-cost production capacity,” stated CannTrust CEO Peter Aceto.

CannTrust is financially ready to tap into the U.S market

The CannTrust CEO also noted that the company will take advantage of its experience in the formulation of standardized CBD products as part of its strategy to enter the U.S market. Mr. Aceto also revealed that his company’s successful equity offering provided enough financial muscle to fuel its ambitious expansion plans.

CannTrust aims to be among the leading and trusted suppliers of high-quality, standardized CBD formulations derived from hemp. The company believes that there will be an increasing demand for high-grade CBD formulations from international retailers. It therefore makes sense to invest in processes that will add value to the end product such as genetic studies and expert growing practices to achieve the highest safety and quality standards.

Elk Grove and CannTrust will each have 50% ownership in their joint operations. Elk Grove is an ideal partner for the endeavor because it has years of farming experience in a variety of products. Its focus includes products designed for crop protection, supply, and input. Its operations are distributed across California, which means that the groundwork has already been laid for the partnership. It will thus be easier for the CannTrust to penetrate into the California market.

Elk Grove executive Morgan Houchin stated that his company was excited about the partnership with CannTrust. He added that his firm’s experience in farming operations will be a great combination with CannTrust’s experience in creating class-leading formulations.

Continue Reading


Rocky Mountain High Brands Inc (OTCMKTS:RMHB) Strikes Broker Deal With Carlin Group



Lifestyle brand management firm Rocky Mountain High Brands Inc (OTCMKTS:RMHB) announced on Wednesday that it secured a broker deal with Carlin Group for its products in the retail space.

The broker agreement will allow Carlin to represent RMHB’s CBD-infused drinks through the HEMPd brand. It will also represent beverages infused with Hempseed extract under RMHB brands. The deal will also cover CBD-infused wellness products such as lotions, water-soluble solutions, capsules, gummies and tinctures as part of the HEMPd brand. Spirit Water will also be covered under the agreement.

The RMHB-Carlin broker deal covers multiple states. They include Missouri, Nebraska, Texas, South Dakota, North Dakota, Minnesota, Wisconsin, Illinois, Pennsylvania, Tennessee, Kentucky, Ohio, Indiana, and Michigan.

“We are very excited about the opportunity to have our entire product line represented by Carlin Group,” stated RMHB CEO Michael Welch.

The Carlin broker deal will boost RMHB’s exposure

Welch noted that the broker deal will strategically allow RMHB to leverage optimal exposure to mass marketers, grocery store chains, convenient stores, major retailers and other types of outlets. The company would not have managed to reach such a wide range of outlets cost-effectively without a broker deal.

The RMHB CEO also added that his company and Carlin will maintain a close collaboration so that they can facilitate retail availability of RMHB products. Welch also revealed that RMHB reviewed numerous other retail introduction options. This was before settling on Carlin which the company believes is the best-suited brand to rapidly get its products onto retail shelves.

Carlin Group’s Managing Director Albert Vergilio noted in a statement that his company was excited to host RMHB and the CBD-based products that are part of its HEMPd brand in Carlin’s new CBD division. He also added that it is part of investing in the future of CBD considering the fast-tracked popularity of CBD products, and the regulations that govern them.

Carlin’s sales team will undergo some training to get them acquainted with RMBH’s products. The sales team will then hold meetings with corporate customers as part of the retail rollout of the products. Sales that will be part of the broker deal are expected to kick off in Q3.

Continue Reading


Wildflower Brands Inc (OTCMKTS:WLDFF) Establishes Footprint Across The US With PO For Hemp CBD Products From Dillard’s Department Stores And Eyes Markets In Texas And Florida



Wildflower Brands Inc (OTCMKTS:WLDFF) has announced establishing a nationwide presence with a PO from Dillard’s Department store. The company has fulfilled the PO received from Dillard.

Hemp CBD products in 292 locations

Dillard’s department store will showcase the premium hemp CBD products of Wildflower in its 292 locations across the US. With its best practices and transparency, Wildflower is eyeing the key markets in Texas and Florida. The company will educate the customers in these regions about salable products. Wildflower has received subsequent orders from Dillard’s and is fulfilling the requirements.

Chief Executive Officer of Wildflower, William Maclean said the supply of CBD infused products to Dillard’s Department stores doubles the existing retail locations in the nation. The company aims to capitalize on its brand to become a household name. It will improve loyalty building because of the reputation and respect of Dillard’s as a retailer. Wildflower aims to provide health and wellness benefits of its CBD infused products to the customers in the US through Dillard’s.

Signs a deal with Highmark Interactive

Wildflower has signed a deal to use EQ – Brain Tracking, mobile software of Highmark Interactive, in the clinical research to study the functional neurological and cognitive effects of CBD. The company aims to get meaningful results and data that help to understand the functional and cognitive neurological properties of the cannabinoids.

William said the company would collect testimonials from the customers on its products that provide the health and wellness needs using plant-based solutions. The company will strive to improve the products, and the research helps it to reach that goal and growth with continued investments.

Acquires City Cannabis Corp

Wildflower has signed an LOI on April 3, 2019, to take over City Cannabis Corp. The company will issue its 60 million common shares for the takeover. The companies will complete the acquisition on receiving advice from corporate, tax, and securities law departments.

The cannabis retailer City Cannabis holds two licenses in the City of Vancouver to market cannabis. It is generating profits through operating dispensaries in Vancouver. The acquisition helps Wildflower to expand retail footprint using the expertise of City Cannabis.

Continue Reading

Trending Stories